Nuphase Pharmaceutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nuphase Pharmaceutics - overview
Established
2024
Location
Shanghai, Shanghai, China
Primary Industry
Pharmaceuticals
About
Founded in 2024 and based in Shanghai, China, Nuphase Pharmaceutics is a pharmaceutical technology company that focuses on the research and development of drugs for difficult-to-drug targets and intractable diseases. In February 2025, the firm raised pre-series A funding led by new investor Pudong Capital. Other returning investor Proxima Ventures also participated in the round. Kevin Liu, the company's co-founder, has more than 30 years of experience in drug development and management in multinational pharmaceutical companies and has entrepreneurial experience in biotechnology companies.
The company's main business is the research and development of drugs for the treatment of autoimmune diseases, central nervous system diseases, tumors, etc. It develops drugs through the CoPIC technology platform and DropScan technology platform. The company’s revenue is generated by providing medicines for difficult-to-druggable targets and intractable diseases. The company will use the funding for advancing pipeline research and development and accelerating the development of its "liquid-liquid phase separation" technology platform.
Current Investors
Proxima Capital, Nest.Bio Labs, Pudong Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.